Effect of Anticoagulants or Antiplatelets Administration on Mortality Case in COVID-19 Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Downloads
Acute ischemic stroke (AIS) is a life-threatening complication of COVID-19. This study aims to compare anticoagulant or antiplatelet administration on mortality cases in patients with COVID-19 and AIS. To know the mortality rate in COVID-19 patients with AIS after anticoagulants or antiplatelets therapies. We searched PubMed, ScienceDirect, and Google Scholar for a retrospective cohort study of anticoagulant or antiplatelet effects on mortality cases in COVID-19 and AIS patients. The retrospective cohort was screened using our eligibility criteria, and quality was assessed using the Newcastle Ottawa Scale. Heterogeneity was assessed using the I2 test, and publication bias was evaluated using a funnel plot. All analyses were performed using Review Manager 5.4. Seven retrospective cohort studies involving 58 patients (38 of whom received anticoagulant therapy) met the inclusion criteria. Our combined analysis showed that anticoagulation versus antiplatelet therapy in COVID-19 patients with AIS on the forest plot chart did not significantly affect mortality (OR: 0.9 95% CI 0.42-1.91 I2=0 %). The study showed no significant difference in the incidence of death between anticoagulants or antiplatelet agents to COVID-19 patients with AIS.
Sweid A, Hammoud B, Bekelis K, Missios S, Tjoumakaris S, Gooch M, et al. Cerebral ischemic and hemorrhagic complications of coronavirus disease 2019. Int J Stroke. 2020;15(7):733–42.
Khandelwal P, Al-Mufti F, Tiwari A, Singla A, Dmytriw AA, Piano M, et al. Incidence, characteristics and outcomes of large vessel stroke in COVID-19 cohort: An international multicenter study. Neurosugery. 2021;89(1):E35–41.
Lapergue B, Lyoubi A, Mesguer E, Avram I, Denier C, Venditti L, et al. Large vessel stroke in six patients following SARS-CoV-2 infection: a retrospective case study series of acute thrombotic complications on stable underlying atherosclerotic disease. Eur J Neurol. 2020;27(11):2308–11.
Yaghi S, Ishida K, Torres J, Grory B, Raz E, Humbert K, et al. SARS-CoV-2 and stroke in a New York healthcare system. Stroke. 2020;51(7):2002–11.
Watson R, Johnson D, Dharia R, Merli G, Doherty J. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: A best practices quality initiative across a large health system. Host Pr. 2020;48(4):169–79.
Bahouth M, Venkatesan A. Acute viral illnesses and ischemic stroke. Stroke. 2021;52(5):1885–94.
Wijeratne T, Crewther S, Sales C, Karimi L. COVID-19 pathophysiology predicts that ischemic stroke occurrence is an expectation, not an exception-a systematic review. Front Neurol. 2021;11:607221.
Colling ME, Kanthi Y. COVID–19-associated coagulopathy: An exploration of mechanisms. Vasc Med. 2020;25(5):471–8.
Shekhar R, Sheikh A, Suriya S, Upadhyay S, Zafar A. Neurological complications among native americans with COVID-19: Our experience at a tertiary care academic hospital in the U.S. J Stroke Cerebrovasc Dis. 2020;29(12):105260.
Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.
Grewal P, Pinna P, Hall JP, Dafer R, Tavarez T, Pellack DR, et al. Acute ischemic stroke and COVID-19: Experience from a comprehensive stroke center in midwest US. Front Neurol. 2020;11(910):1–7.
Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020;5(3):279–84.
Copyright (c) 2022 Galuh Anis Tasya, Farhan Haidar Fazlur Rahman, Vita Kusuma Rahmawati
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
